Novartis milestones be proud ! Management take a bow !

PAY UP SUCKAS !

Novartis Pays $99M To Settle Overtime Rep Suit
By Ed Silverman // January 25th, 2012 // 10:46 am

More than a year after a federal appeals court ruled that Novartis sales reps are not exempt from overtime provisions of the Fair Labor Standards Act and, therefore, should be paid overtime (back story), the drugmaker has agreed to a $99 million settlement, according to lawyers for the reps.

The move is significant because, until now, drugmakers have been fighting efforts by their current and former sales reps to win overtime pay. The topic has divided the courts and there have been so many conficting rulings that the US Supreme Court agreed last November to review the debate (look here). A ruling is expected this summer. Ironically, the Supreme Court had earlier declined to review the decision in the Novartis case (here is the 2006 lawsuit filed by the Novartis reps).
 






FDA chides Novartis on drug promotion

Wed Jan 25, 2012 6:13pm EST

(Reuters) - Health regulators said drugmakers Celgene Corp and Novartis AG misrepresented their cancer drugs to doctors, overstating how well the medicines targeted tumors without having evidence to support it.

The complaints concern Novartis's cancer drug Gleevec.

The Food and Drug Administration posted a letters to the company on its website on Wednesday, asking them to stop using advertising that violates FDA guidelines.

The FDA inspects companies' marketing materials to make sure they do not illegally promote drugs for uses other than those approved by the agency, or make false claims that are not backed by clinical data.

For Novartis, the FDA focused on a "Case Highlights" document that described how well Gleevec worked for a particular patient. The FDA said this was misleading because the document implied the drug would work just as well for other patients.

"A selected case study of one patient's treatment response does not constitute substantial evidence," the FDA said in the letter.

Novartis said that it had responded to the FDA's letter, but the company did not divulge the nature of its response.

(Reporting by Anna Yukhananov; Editing by Gerald E. McCormick and Steve Orlofsky)
 






NOVARTIS KILLS YOUR DOG TOO !

>: - (

FDA Recalls / Safety Alerts
Novartis Warns Of Wrong Tablets In Pet Medicine Clomicalm Bottles

1/31/2012 6:38 AM ET
(RTTNews) - It's been only a few days since the consumer health division of Swiss drug maker Novartis AG (NVS: News ) temporarily suspended operations at Lincoln, Nebraska, production facility and recalled certain over-the-counter drugs - Bufferin, Excedrin, Gas-X Prevention and NoDoz, due to mix-up of products. Now, the animal health division of Novartis has warned that a wrong tablet may be found in bottles of Clomicalm, which is prescribed to treat behavioral disorders in dogs.

On January 25, Novartis Animal Health US, Inc. warned that due to potential packaging issues at its manufacturing facility, there is a rare possibility that a wrong tablet may be found in bottles of Clomicalm. The animal health unit of Novartis said that it has not received any reports where a patient experienced a product mix-up, or any reports of adverse events attributable to a product mix-up.

As a precautionary measure, Novartis is recommending that before dispensing Clomicalm, the contents of the bottle should be examined for tablets that are broken or incorrect in color, shape or size.

The animal health products affected include, Interceptor Flavor Tabs, Sentinel Flavor Tabs, Clomicalm, Program Tablets and Suspension, and Milbemite. Production of Deramaxx, which was recently moved to the site, is also affected.
 












ANOTHER 120 MILLION DOWN THE DRAIN BY THESE INCOMPETENT BOOB EXECUTIVES

FDA report shows deep problems at closed Novartis Consumer Health plant
February 6, 2012 — 10:58pm ET | By Eric Palmer

With the completion of inspections Jan. 20, Novartis Consumer Health (NVS) set about reviewing the 483 FDA observations of its idled plant in Lincoln, NE.

The plant was voluntarily closed Dec. 19 to address a multitude of problems that have led to several recalls of Novartis over-the-counter products, including the entire Excedrin line. The plant also made pain killers for Endo Pharmaceuticals ($ENDP), which has been affected by the closure.

In a statement Monday, Novartis officials said "maintenance and improvements at the Lincoln site, where we voluntarily suspended production on December 19, 2011, to strengthen standards" are ongoing. The officials said the company was "committed to ensuring the highest standard for consumers who rely on our products, and will continue to work with the FDA to fully address their concerns." Novartis has set aside $120 million to address shortcomings at the plant and CEO Joseph Jimenez (photo) has told the investment community

FDA says so far the Novartis "Quality Unit has failed in the responsibility and authority to monitor Quality systems designed to assure the quality of drug products manufactured and packaged at [the] firm."
 






Gilenya Deaths: Novartis is at it again

February 1, 2012
Posted In: , by JONES WARD PLC

By JONES WARD PLC on February 1, 2012 7:46 PM | Permalink

Novartis has another ticking time bomb on its hand, with an MS drug that has caused more than 11 people to die, according to Novartis sales reps. Gilenya (fingolimod) is used to prevent episodes of symptoms and slow the worsening of disability in patients with relapsing forms (course of disease where symptoms flare up from time to time) of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control). Fingolimod is in a class of medications called sphingosine l-phosphate receptor modulators. It works by decreasing the action of immune cells that may cause nerve damage.

Based upon my sources, the sales reps are not happy with the way the company is handling the side effects of this drug. Doctors are getting nervous about it too.

In reality, it is amazing that this drug ever made it on to the market. According to this study, there were 84 deaths during the clinical trials. http://www.ema.europa.eu/docs/en_GB/...C500104529.pdf Wow! Something tells me that this drug may end up being recalled.

The deaths of the patients have led regulators to be concerned that Gilenya may trigger heart problems, especially after patients have taken their first dose. One patient reportedly died within 24 hours of taking the drug. In November 2011, a patient died in the USA in an event that may have been related to the drug or for other reasons. This remains the subject of an FDA investigation.

The investigation into the ill-health effects and into Novartis is being undertaken by the European Medicines Agency (EMA), which has similar status to the U.S. Food and Drug Administration (FDA). The EMA is expected to conclude its investigation in March. In addition to the European concerns, Fox News have reported that the FDA are also conducting their own data analysis and will make an announcement about the use of Gilenya in the near future.
 






NICE and the FDA/OIG need to "re-call" the senior management team, board of directors, and joe and dan, of Novartis, and put their behinds in jail! Better that, ban them to a small compound in the middle of a destitute desert with the other Ponzi creators and criminals and see who gets screwed then!
 












Shareholder group slams Novartis over chairman's pay
Thu Feb 2, 2012 12:22pm EST

* Ethos urges investors to vote out Novartis board members

* Chairman's pay rose while net profit dropped

* Ethos renews calls for UBS investment bank head to quit (Adds Novartis comment)

By Katharina Bart

ZURICH, Feb 2 (Reuters) - Shareholder group Ethos called for Novartis investors to vote against re-electing board members who were among those deciding on the pay awarded to the Swiss drugmaker's chairman, Daniel Vasella.

The call is part of an attack on Vasella for "earning a million Swiss francs a month, which goes too far," Ethos director Dominique Biedermann told journalists in Zurich.

Vasella's pay rose to 13.5 million Swiss francs ($14.8 million) in 2011, when Novartis' profit fell 7 percent, from roughly 12 million Swiss francs the year prior.

Novartis does not conduct a say-on-pay vote annually, though it did so in 2010. Ethos, which is influential because it makes recommendations to Swiss pension funds, said shareholders should vote against the re-election of board members William Brody and Srikant Datar, two members of the compensation committee who are up for re-election.

In a detailed response, Novartis said board pay is comparable to healthcare companies and other Swiss blue-chips such as UBS AG and Nestle AG, and that the chairman's role is a full-time job requiring exceptional industry "expertise".


EXPERTISE ? REALLY ? EXPERTISE THAT KILLS PATIENTS , RACKS UP BILLIONS IN FINES & OFFERS SUB STANDARD MEDS FROM FILTHY CONTAMINATED PLANTS
 






Novartis Hit By US Delay To Meningitis Vaccine Menveo

FEBRUARY 13, 2012, 5:43 A.M. ET

ZURICH (Dow Jones)--Novartis AG (NVS) Monday said the U.S. drug regulator has asked for further information on the use of its Menveo meningitis vaccine in infants, potentially delaying its extended use in the U.S.

"We submitted the supplemental application for Menveo to the FDA [Food and Drug Administration] in April 2011, and the FDA has completed the current review cycle, and requests answers to additional questions prior to proceeding with it," the Swiss drug maker said in a statement Monday.

The latest application is for use in infants and toddlers from two months, it said.

"This additional delay further postpones approval in this all-important age group, and puts it at a further disadvantage to [rival] Sanofi's [SNY] Menactra," according to Karl-Heinz Koch, an analyst at Helvea.
 












NICE HOB HIMENEZ !!!

Shortages likely as Sandoz' Canadian plant woes continue

Published on 20/02/12 at 11:48am

Ongoing compliance problems at a plant in Canada operated by Novartis' generics subsidiary Sandoz look set to cause supply disruptions for a number of products.

Sandoz has said it plans to stop production of non-essential medicines made at the Boucherville facility in Quebec and concentrate on essential products to try to ease the situation, caused by suspension of most of the production capacity at the plant.

Towards the end of last year Novartis was sent a warning letter by the FDA, saying that inspections had revealed evidence that three North American facilities were not meeting Good Manufacturing Practice (GMP) standards.

Problems cited in the letter included microbial contamination of purportedly sterile drug products, a lack of written procedures designed to prevent contamination, not investigating batch failures properly and deficiencies in the operations of the quality control unit.

The Boucherville site employs 800 staff and specialises in generic sterile injectable pharmaceuticals, with a portfolio of more than 100 products including narcotics, sedatives, antibiotics and ophthalmic agents.

The other sites pulled up by the FDA were both in the US, at Broomfield, Colorado, and Wilson, North Carolina. Sandoz has said it intends to spend around $170 million refurbishing and upgrading the facilities and maintains it has no intention of closing the Boucherville plant.

Sandoz said in a statement released on Saturday that it will have to manage a temporary but significant reduction in output from the Boucherville facility, but is working to restore full production levels ‘as soon as possible’.

The company has decided to stop production of ointment, ophthalmic and suppository formulations of non-essential drugs and concentrate on critical products such as pain-relief medicines, cancer drugs and anti-infectives.
 






WOW !!! NOVARTIS INEPTNESS SCREWS OTHER COMPANIES TOO !

Glaxo recalls hypertension drug made at Novartis plant

24 Feb 2012 23:35


Feb 24 (Reuters) - GlaxoSmithKline has recalled 394,230 bottles of its DynaCirc CR hypertension drug from the U.S. market after the manufacturer, Novartis, reported inconsistent packaging practices.

The generic drug is manufactured at a Novartis plant in Lincoln, Nebraska.
 






PROFITS DOWN = DIVIDENDS UP !! NICE STRATEGY TO KEEP THE INCOMPETENT B.O.D.'s

Shareholders approve all proposed resolutions of Novartis Board of Directors
Thu Feb 23, 2012 7:08am EST


Novartis International AG / Shareholders approve all proposed resolutions of Novartis Board of Directors . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Shareholders approve 15th consecutive dividend increase to CHF 2.25 (+2%) per share for 2011, representing a payout of approximately 63% of net income from continuing operations

Novartis reaffirms Group outlook; renews commitment to consistently meet quality standards across manufacturing operations (BWAHAHAHAHAHAHHAHAHAHA !!)

Dr. Dimitri Azar elected as new member of the Novartis Board of Directors for a three year term

Drs. Srikant Datar, Andreas von Planta and Wendelin Wiedeking re-elected for three-year term each; Drs William Brody and Rolf M. Zinkernagel re-elected for two-year term each

Basel, February 23, 2012 - Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting. Shareholders approved the fifteenth consecutive dividend increase of 2% to CHF 2.25 for 2011, marking a continued increase in the dividend per share since the creation of Novartis in 1996.

A total of 1,896 shareholders were present at the meeting held in Basel, representing approximately 1,45 billion shares or 52.8% of the almost 2,75 billion issued shares of Novartis.

"The 2011 business environment remained uncertain, impacted by governmental budget deficits, considerable currency turbulence and greater regulatory scrutiny. Building on an attractive business portfolio, Novartis remains nevertheless successful, focusing on innovation and geographic expansion. New and recently launched products continued to be key growth drivers in 2011 and hold more promise for the future," said Dr. Daniel Vasella, Chairman of Novartis.

Shareholders approved a dividend payment of CHF 2.25 per share for 2011 compared to CHF 2.20 in 2010, representing a payout ratio of approximately 63% of net income from continuing operations. Payment for the 2011 dividend will be made with effect from March 1, 2012.
 






PATIENTS LIVES VS. NOVARTIS GREED


MSF seeks Novartis' shareholders to urge company to drop ongoing patent case against India

Ramesh Shankar, Mumbai
Friday, February 24, 2012, 08:00 Hrs [IST]

The international medical humanitarian organization Médecins Sans Frontières (MSF) has called upon the shareholders of Swiss pharmaceutical company Novartis to urge the company to drop its ongoing court case against the Indian government as the case could have a severe impact on access to affordable medicines for people across the developing world.

The MSF's clarion call in this regard comes in the wake of the shareholders meet of Novartis on February 23 in Basel, Switzerland.

In the Supreme Court of India, Novartis is challenging Section 3(d) of India's Patents Act which prohibits 'evergreening' - the practice of multinational pharmaceutical companies to extend their patent terms by making small, trivial changes to existing medicines and thereby preventing access to generic affordable drugs. Under Section 3(d), patents will not be granted for new uses or new forms of existing medicines
 






THE NOVARTIS CHARADE DO INVESTORS KNOW ???!!! NO WONDER EXECS ARE MILKING THE CASH & CASHING IN OPTIONS

Can the Drug Companies Keep Up the Charade?

By Bruce Krasting Feb 27, 2012, 8:18 AM

An interesting article in the Swiss press this morning regarding the big Swiss drug companies, Roche and Novartis (NVS).
Apparently the PIGS are not paying their drug bills. The numbers are big. The bills have been unpaid for years. Some excerpts from the article:

Hospitals in Portugal, Italy, Greece and Spain are delaying paying for drugs by up to three years.
Three years??
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), European states owe €12-15 billion (SFr14.4-18 billion) to the pharma industry, which includes groups like Roche and Novartis.

$20 billion of unpaid drug bills??
A number of public hospitals and state insurance schemes are close to bankruptcy. But before being unable to pay staff salaries they stop paying suppliers,” Ignazio Cassis, vice-president of the Swiss Medical Association.
Hospitals and state managed health insurers are bankrupt?? This came as a bit of a shocker to me:

The number of unpaid bills from Spain, Portugal and Italy increased last year, while those from Greece fell as a result of ‘zero coupon bonds’ issued by Athens, Roche spokeswoman Claudia Schmitt said.
WHAT?? Greece is issuing zero coupon bonds? Bonds, not trade payable debt? To pay for drugs? How many zero coupon bonds has Greece issued? What are the terms for these bonds?

This whole story blows me away. I’m not surprised that the bankrupt PIGS are late payers. But three-years? That’s ridiculous. If the PIGS are stiffing drug companies, who else are they stiffing? Are they paying for the oil they use? Food? How big are these trade IOUs?
Nearly every day we get some story about the progress being made to address the financial ills of the weak European countries. Last week it was the phony Greek restructuring deal (it won’t happen). This weekend the talk is for Trillions of dollars from the IMF. Complete rubbish. The USA has said it will not put up a dime, so there is no IMF option.

You have guys like Tim Geithner saying silly stuff like this over the weekend:
“I hope that we’re going to see, and I expect we will see continued efforts by the Europeans … to put in place a stronger, more credible firewall.”
“Firewalls” indeed. Tim boy is worried about the sovereign bonds issued by the PIGS. He knows that if the Sov. bonds go tapioca, the lights will go off in the USA. But the reality is that the problem has extended far beyond bonds; the PIGS are not paying trade creditors. Timmy is just making noise about ring fencing debt.

Where does this go? Can the drug companies keep up the charade? If one of the big pharmas breaks, and says, “No more IOUs, we want cash”, then they all will. At that point, things come apart very quickly. From the article:
Swiss pharmaceutical giants Roche and Novartis are examining whether to limit supplies.
This is a very sensitive issue. If the drug companies cut supplies, there will be hell to pay. These companies do not want to take a public position on this issue, they could become a target by demonstrators in the PIGS. The Swiss druggies avoid the publicity problem by having their trade group SMA, do the talking for them. I thought there was a very blunt tone to these words:

Pharma companies are private. In a liberal, democratic society respect for private property is a fundamental value. Private firms are the only ones able to weigh the pros and cons of stopping the supply of certain medicines.
Really? The drug companies are the only ones with a vote? Wanna bet?
If the drug companies do limit supplies, there will be consequences. The question of whether or not the PIGS are, in fact, liberal democratic societies, will be put to the test. In the process, I wouldn’t be surprised if the issue of whether the drug makers are public or private is also tested.

Note #1
I was part of the problem (and part of the solution) for the Latin American debt crisis of the 80’s. I had a front row seat with each central bank as they went bust. Every effort was made to kick the financial can down the road. In the end, it all blew up.
For every country, the death march was the same. When big trade creditors finally balked, and said, “No mas IOU”, debt default followed within weeks.

Note #2
Novartis and Roche have the PIG “trade receivables” and those Greek “Zeros” on the books at 100% of par. The other global drug companies who are sitting on the rest of the $20b of IOUs have it booked the same. These debts are not worth par. One day these drug companies will have to write them off. I do wonder what other big EU companies are sitting on chunky IOU’s from PIGS. None of this is “money good”. Novartis had this to say:

Deteriorating credit and economic conditions and other factors in these countries may require us to re-evaluate the collectability of these receivables in future periods.
 






The Swiss Stock Market Finished In The Red Monday Due To Novartis Weakness
2/28/12

(RTTNews.com) - The Swiss stock market closed to the downside Monday, despite a recovery late in the day. The negative finish was largely attributed to the weak performance by shares of Novartis, one of the heaviest weighted stocks in the SMI.
The Swiss Market Index fell by 0.65% Monday and finished at 6,143. The Swiss Leader Index dropped by 0.43% and the Swiss Performance closed lower by 0.06%.

Shares of Novartis decline by 3.5% on Monday and was responsible for the majority of the weakness in the SMI. The loss was attributed to a reduction in the company's dividend. Roche also finished down by 0.02%
 






BECAUSE HE DID SUCH A GOOD JOB AS KINCOLN NEBRASKA DEMONSTRATES
& AS USUAL ANOTHER NVS FEMALE BITES THE DUST

3/5/2012

Novartis has promoted Brian McNamara from region head of its European over-the-counter (OTC) business to head of its entire OTC division.

McNamara replaces Naomi Kelman who Novartis said had decided to leave the company. She had only been in the position since March 2011 after joining from Johnson & Jonson (J&J).

In a statement, Joseph Jimenez, CEO of Novartis, thanked Kelman for her work, and welcomed McNamara as someone who will “provide strong leadership, focusing on growing our priority brands, consistently meeting our quality standards, and improving performance in key emerging markets”.

McNamara has been at Novartis OTC since 2004, when he joined as senior VP and general manager of OTC North America.

He spent three years in the position before moving to Europe as president and region head of Novartis OTC Europe.

Prior to his time at Novartis, he spent 16 years at Procter and Gamble, working in both manufacturing management and brand management.

His appointment comes just two months after Novartis recalled batches of four OTC products in the US following complaints of chipped and broken pills as well as well as inconsistent clearance practices for bottle packaging at a its Lincoln, Nebraska, manufacturing plant.

Novartis temporarily suspended operations at the facility following a warning letter from the US Food and Drug Administration (FDA).

GlaxoSmithKline (GSK) has also been affected by issues at the plant, and was forced to recall nearly 400,000 bottles of its blood pressure treatment DynaCirc CR that made there.
 






THE NOVARTIS CHARADE DO INVESTORS KNOW ???!!! NO WONDER EXECS ARE MILKING THE CASH & CASHING IN OPTIONS

Can the Drug Companies Keep Up the Charade?

By Bruce Krasting Feb 27, 2012, 8:18 AM

An interesting article in the Swiss press this morning regarding the big Swiss drug companies, Roche and Novartis (NVS).
Apparently the PIGS are not paying their drug bills. The numbers are big. The bills have been unpaid for years. Some excerpts from the article:

Hospitals in Portugal, Italy, Greece and Spain are delaying paying for drugs by up to three years.
Three years??
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), European states owe €12-15 billion (SFr14.4-18 billion) to the pharma industry, which includes groups like Roche and Novartis.

$20 billion of unpaid drug bills??
A number of public hospitals and state insurance schemes are close to bankruptcy. But before being unable to pay staff salaries they stop paying suppliers,” Ignazio Cassis, vice-president of the Swiss Medical Association.
Hospitals and state managed health insurers are bankrupt?? This came as a bit of a shocker to me:

The number of unpaid bills from Spain, Portugal and Italy increased last year, while those from Greece fell as a result of ‘zero coupon bonds’ issued by Athens, Roche spokeswoman Claudia Schmitt said.
WHAT?? Greece is issuing zero coupon bonds? Bonds, not trade payable debt? To pay for drugs? How many zero coupon bonds has Greece issued? What are the terms for these bonds?

This whole story blows me away. I’m not surprised that the bankrupt PIGS are late payers. But three-years? That’s ridiculous. If the PIGS are stiffing drug companies, who else are they stiffing? Are they paying for the oil they use? Food? How big are these trade IOUs?
Nearly every day we get some story about the progress being made to address the financial ills of the weak European countries. Last week it was the phony Greek restructuring deal (it won’t happen). This weekend the talk is for Trillions of dollars from the IMF. Complete rubbish. The USA has said it will not put up a dime, so there is no IMF option.

You have guys like Tim Geithner saying silly stuff like this over the weekend:
“I hope that we’re going to see, and I expect we will see continued efforts by the Europeans … to put in place a stronger, more credible firewall.”
“Firewalls” indeed. Tim boy is worried about the sovereign bonds issued by the PIGS. He knows that if the Sov. bonds go tapioca, the lights will go off in the USA. But the reality is that the problem has extended far beyond bonds; the PIGS are not paying trade creditors. Timmy is just making noise about ring fencing debt.

Where does this go? Can the drug companies keep up the charade? If one of the big pharmas breaks, and says, “No more IOUs, we want cash”, then they all will. At that point, things come apart very quickly. From the article:
Swiss pharmaceutical giants Roche and Novartis are examining whether to limit supplies.
This is a very sensitive issue. If the drug companies cut supplies, there will be hell to pay. These companies do not want to take a public position on this issue, they could become a target by demonstrators in the PIGS. The Swiss druggies avoid the publicity problem by having their trade group SMA, do the talking for them. I thought there was a very blunt tone to these words:

Pharma companies are private. In a liberal, democratic society respect for private property is a fundamental value. Private firms are the only ones able to weigh the pros and cons of stopping the supply of certain medicines.
Really? The drug companies are the only ones with a vote? Wanna bet?
If the drug companies do limit supplies, there will be consequences. The question of whether or not the PIGS are, in fact, liberal democratic societies, will be put to the test. In the process, I wouldn’t be surprised if the issue of whether the drug makers are public or private is also tested.

Note #1
I was part of the problem (and part of the solution) for the Latin American debt crisis of the 80’s. I had a front row seat with each central bank as they went bust. Every effort was made to kick the financial can down the road. In the end, it all blew up.
For every country, the death march was the same. When big trade creditors finally balked, and said, “No mas IOU”, debt default followed within weeks.

Note #2
Novartis and Roche have the PIG “trade receivables” and those Greek “Zeros” on the books at 100% of par. The other global drug companies who are sitting on the rest of the $20b of IOUs have it booked the same. These debts are not worth par. One day these drug companies will have to write them off. I do wonder what other big EU companies are sitting on chunky IOU’s from PIGS. None of this is “money good”. Novartis had this to say:

Deteriorating credit and economic conditions and other factors in these countries may require us to re-evaluate the collectability of these receivables in future periods.

Toxic receivables should be disclosed on NVS year end or should be considered fraud by the SEC
 






PFIZER TO NVS , FUCK OFF & BOLT ON THIS

Updated March 7, 2012, 6:19 p.m. ET.

Pfizer Spurned Novartis Bid for Its Animal-Health Unit

By DANA CIMILLUCA And GINA CHON

Novartis AG recently made an approach to buy Pfizer Inc.'s sprawling animal-health business, which, if sold, could fetch between $15 billion and $20 billion, according to people familiar with the matter.

The preliminary offer, made roughly within the past month and valued at as much as $16 billion, was rebuffed as too low
A spokeswoman for Novartis said the company "is focusing on its previously communicated strategy of seeking bolt-on acquisitions "